JP7855521B2 - ヒト抗ｃｄ３３抗体及びその使用 - Google Patents

ヒト抗ｃｄ３３抗体及びその使用

Info

Publication number
JP7855521B2
JP7855521B2 JP2022559585A JP2022559585A JP7855521B2 JP 7855521 B2 JP7855521 B2 JP 7855521B2 JP 2022559585 A JP2022559585 A JP 2022559585A JP 2022559585 A JP2022559585 A JP 2022559585A JP 7855521 B2 JP7855521 B2 JP 7855521B2
Authority
JP
Japan
Prior art keywords
containing seq
seq
antibody
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520399A (ja
JP2023520399A5 (enExample
Inventor
ウォルター，ローランド・ビー
ラースロー，ジョージ・エス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of JP2023520399A publication Critical patent/JP2023520399A/ja
Publication of JP2023520399A5 publication Critical patent/JP2023520399A5/ja
Priority to JP2026071149A priority Critical patent/JP2026123131A/ja
Application granted granted Critical
Publication of JP7855521B2 publication Critical patent/JP7855521B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022559585A 2020-03-31 2021-03-31 ヒト抗ｃｄ３３抗体及びその使用 Active JP7855521B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026071149A JP2026123131A (ja) 2020-03-31 2026-04-22 ヒト抗ｃｄ３３抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003203P 2020-03-31 2020-03-31
US63/003,203 2020-03-31
PCT/US2021/025220 WO2021202770A2 (en) 2020-03-31 2021-03-31 Human anti-cd33 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026071149A Division JP2026123131A (ja) 2020-03-31 2026-04-22 ヒト抗ｃｄ３３抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2023520399A JP2023520399A (ja) 2023-05-17
JP2023520399A5 JP2023520399A5 (enExample) 2024-03-28
JP7855521B2 true JP7855521B2 (ja) 2026-05-08

Family

ID=77929454

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559585A Active JP7855521B2 (ja) 2020-03-31 2021-03-31 ヒト抗ｃｄ３３抗体及びその使用
JP2026071149A Pending JP2026123131A (ja) 2020-03-31 2026-04-22 ヒト抗ｃｄ３３抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026071149A Pending JP2026123131A (ja) 2020-03-31 2026-04-22 ヒト抗ｃｄ３３抗体及びその使用

Country Status (6)

Country Link
US (1) US12662546B2 (enExample)
EP (1) EP4126248A4 (enExample)
JP (2) JP7855521B2 (enExample)
CN (1) CN115397515A (enExample)
CA (1) CA3173205A1 (enExample)
WO (1) WO2021202770A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
JP7840865B2 (ja) * 2020-03-31 2026-04-06 フレッド ハッチンソン キャンサー センター キメラ抗原受容体ターゲティングｃｄ３３
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
PE20241343A1 (es) * 2021-10-15 2024-07-03 Cytomx Therapeutics Inc Complejo polipeptidico activable
AU2023289376A1 (en) * 2022-06-22 2025-01-16 Eli Lilly And Company Human cd33 antibodies and glucocorticoid conjugates
CN121591894A (zh) * 2024-08-23 2026-03-03 南京北恒生物科技有限公司 靶向cd33的抗体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018211245A1 (en) 2017-05-15 2018-11-22 Autolus Limited Cell
WO2018218207A1 (en) 2017-05-26 2018-11-29 Fred Hutchinson Cancer Research Center Anti-cd33 antibodies and uses thereof
JP2019532017A (ja) 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
JP2020509050A (ja) 2017-02-28 2020-03-26 ブイオーアール バイオファーマ, インコーポレーテッドVor Biopharma, Inc. 系統特異的タンパク質の阻害のための組成物および方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
WO2007045465A1 (en) 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
WO2008007755A1 (en) 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
DE102009045006A1 (de) * 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
AR098743A1 (es) 2013-12-13 2016-06-08 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN108064245A (zh) 2015-04-17 2018-05-22 埃尔萨里斯生物技术公司 抗Tyro3抗体及其用途
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
TW201800420A (zh) 2016-05-20 2018-01-01 艾伯維史坦森特瑞斯有限責任公司 抗ascl1抗體及使用方法
US20190038248A1 (en) 2017-08-04 2019-02-07 Dentalaire Products Int'l Veterinary X-ray Sensor and Boot
US20200063100A1 (en) * 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CA3173213A1 (en) 2020-03-31 2021-10-07 Roland B. WALTER Anti-cd33 antibodies and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532017A (ja) 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
JP2020509050A (ja) 2017-02-28 2020-03-26 ブイオーアール バイオファーマ, インコーポレーテッドVor Biopharma, Inc. 系統特異的タンパク質の阻害のための組成物および方法
WO2018211245A1 (en) 2017-05-15 2018-11-22 Autolus Limited Cell
WO2018218207A1 (en) 2017-05-26 2018-11-29 Fred Hutchinson Cancer Research Center Anti-cd33 antibodies and uses thereof

Also Published As

Publication number Publication date
CN115397515A (zh) 2022-11-25
EP4126248A2 (en) 2023-02-08
US20230144405A1 (en) 2023-05-11
JP2023520399A (ja) 2023-05-17
WO2021202770A2 (en) 2021-10-07
US12662546B2 (en) 2026-06-23
EP4126248A4 (en) 2024-07-10
WO2021202770A3 (en) 2021-11-11
JP2026123131A (ja) 2026-07-29
CA3173205A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CN113286879B (zh) 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子
JP7323102B2 (ja) 抗ｐｓｍａ抗体およびその使用
JP7851255B2 (ja) 抗ｃｄ３３抗体及びその使用
US20250034250A1 (en) Anti-cd33 antibodies and uses thereof
TWI718118B (zh) 針對ｒｏｒ１之特異性抗體及嵌合抗原受體
US20230144405A1 (en) Human anti-cd33 antibodies and uses thereof
WO2022026759A1 (en) T cells and chimeric stimulating receptors and uses thereof
WO2023235772A2 (en) Humanized anti-cd45 antibodies and uses thereof
KR102957804B1 (ko) Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법
TW202342734A (zh) 具有抗-cd19/抗-cd22嵌合抗原受體之基因工程細胞及其用途
JP7859985B2 (ja) Ｃｄ３３を標的にするキメラ抗原受容体
JP2024505428A (ja) Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
JP7840865B2 (ja) キメラ抗原受容体ターゲティングｃｄ３３
JP2024546875A (ja) 二連型ｍｈｃ標的化ｔ細胞エンゲージャー
EP4341702A2 (en) Structure based isolation of pmhc-restricted antibodies
WO2025255276A1 (en) Anti-whitlow linker binding domains and uses thereof
WO2025264864A1 (en) Human anti-cd45 antibodies and uses thereof
WO2025097015A1 (en) Clec2a-binding therapeutics
HK40109256A (en) Multispecific anti-tcr delta variable 1 antibodies
WO2025207798A1 (en) Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
HK40117036A (en) Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
JP2025530110A (ja) 二重特異性ポリペプチド及びその使用
HK40104904A (en) Anti-tcr delta variable 1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260422

R150 Certificate of patent or registration of utility model

Ref document number: 7855521

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150